Liver metastases are the most frequent malignant liver lesions. Besides colorectal carcinoma, gastric carcinoma, pancreatic carcinoma, breast cancer, lung cancer, and neuroendocrine tumors are the most common entities that metastasize to the liver. The morphology of these metastases depends on the primary tumor. For morphologic and functional imaging of non-colorectal liver metastases, multiple imaging techniques such as ultrasonography, computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography coupled with CT or MRI are available. This review summarizes morphologic and functional characteristics of different non-colorectal liver metastases.

Keywords:
Computed tomography, CT, Liver metastases, Magnetic resonance imaging, MRI, Positron emission tomography, PET, Ultrasonography
1.
Imam K, Bluemke DA: MR imaging in the evaluation of hepatic metastases. Magn Reson Imaging Clin N Am 2000;8:741-756.
2.
Abrams HL, Spiro R, Goldstein N: Metastases in carcinoma; analysis of 1000 autopsied cases. Cancer 1950;3:74-85.
3.
Prokop M, Galanski M, Schaefer-Prokop CM, Van der Molen AJ: Ganzkörper-Computertomographie: Spiral- und Multislice-CT. Stuttgart, Thieme, 2007.
4.
Danet IM, Semelka RC, Leonardou P, Braga L, Vaidean G, Woosley JT, Kanematsu M: Spectrum of MRI appearances of untreated metastases of the liver. AJR Am J Roentgenol 2003;181:809-817.
5.
Choi J: Imaging of hepatic metastases. Cancer Control 2006;13:6-12.
6.
Oldenburg A, Hohmann J, Foert E, Skrok J, Hoffmann CW, Frericks B, Wolf KJ, Albrecht T: Detection of hepatic metastases with low MI real time contrast enhanced sonography and SonoVue. Ultraschall Med 2005;26:277-284.
7.
Kinkel K, Lu Y, Both M, Warren RS, Thoeni RF: Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology 2002;224:748-756.
8.
Albrecht T, Blomley MJ, Burns PN, Wilson S, Harvey CJ, Leen E, Claudon M, Calliada F, Correas JM, LaFortune M, Campani R, Hoffmann CW, Cosgrove DO, LeFevre F: Improved detection of hepatic metastases with pulse-inversion US during the liver-specific phase of SHU 508A: multicenter study. Radiology 2003;227:361-370.
9.
Hohmann J, Albrecht T, Oldenburg A, Skrok J, Wolf KJ: Liver metastases in cancer: detection with contrast-enhanced ultrasonography. Abdom Imaging 2004;29:669-681.
10.
Gaa J, Wieder H, Schwaiger M, Rummeny EJ: Modern imaging for liver metastases from colorectal tumors (Article in German). Chirurg 2005;76:525-526, 528-534.
11.
Kamel IR, Georgiades C, Fishman EK: Incremental value of advanced image processing of multislice computed tomography data in the evaluation of hypervascular liver lesions. J Comput Assist Tomogr 2003;27:652-656.
12.
Cantisani V, Grazhdani H, Fioravanti C, Rosignuolo M, Calliada F, Messineo D, Bernieri MG, Redler A, Catalano C, D'Ambrosio F: Liver metastases: contrast-enhanced ultrasound compared with computed tomography and magnetic resonance. World J Gastroenterol 2014;20:9998-10007.
13.
Namasivayam S, Martin DR, Saini S: Imaging of liver metastases: MRI. Cancer Imaging 2007;7:2-9.
14.
Ba-Ssalamah A, Fakhrai N, Matzek WK, Herneth AM, Stadler A, Bastati N, Herold CJ, Schima W: Magnetic resonance imaging of liver malignancies. Top Magn Reson Imaging 2007;18:445-455.
15.
Goodwin MD, Dobson JE, Sirlin CB, Lim BG, Stella DL: Diagnostic challenges and pitfalls in MR imaging with hepatocyte-specific contrast agents. Radiographics 2011;31:1547-1568.
16.
Kanematsu M, Goshima S, Watanabe H, Kondo H, Kawada H, Noda Y, Moriyama N: Diffusion/perfusion MR imaging of the liver: practice, challenges, and future. Magn Reson Med Sci 2012;11:151-161.
17.
Sandrasegaran K, Akisik FM, Lin C, Tahir B, Rajan J, Aisen AM: The value of diffusion-weighted imaging in characterizing focal liver masses. Acad Radiol 2009;16:1208-1214.
18.
Miller FH, Hammond N, Siddiqi AJ, Shroff S, Khatri G, Wang Y, Merrick LB, Nikolaidis P: Utility of diffusion-weighted MRI in distinguishing benign and malignant hepatic lesions. J Magn Reson Imaging 2010;32:138-147.
19.
Hardie AD, Naik M, Hecht EM, Chandarana H, Mannelli L, Babb JS, Taouli B: Diagnosis of liver metastases: value of diffusion-weighted MRI compared with gadolinium-enhanced MRI. Eur Radiol 2010;20:1431-1441.
20.
Shimada K, Isoda H, Hirokawa Y, Arizono S, Shibata T, Togashi K: Comparison of gadolinium-EOB-DTPA-enhanced and diffusion-weighted liver MRI for detection of small hepatic metastases. Eur Radiol 2010;20:2690-2698.
21.
Frankel TL, Gian RK, Jarnagin WR: Preoperative imaging for hepatic resection of colorectal cancer metastasis. J Gastrointest Oncol 2012;3:11-18.
22.
Khalil HI, Patterson SA, Panicek DM: Hepatic lesions deemed too small to characterize at CT: prevalence and importance in women with breast cancer. Radiology 2005;235:872-878.
23.
Sacks A, Peller PJ, Surasi DS, Chatburn L, Mercier G, Subramaniam RM: Value of PET/CT in the management of liver metastases, part 1. AJR Am J Roentgenol 2011;197:W256-259.
24.
Kwekkeboom DJ, Kam BL, van Essen M, Teunissen JJ, van Eijck CH, Valkema R, de Jong M, de Herder WW, Krenning EP: Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer 2010;17:R53-73.
25.
Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schafer M, Schilling T, Haufe S, Herrmann T, Haberkorn U: Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007;34:1617-1626.
26.
Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, Brandau W, Bockisch A, Boy C: 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. J Nucl Med 2011;52:1864-1870.
27.
Klasen J, Heusner TA, Riegger C, Reichelt D, Kuhlemann J, Antoch G, Blondin D: Modern CT and PET/CT imaging of the liver (Article in German). Radiologe 2011;51:671-679.
28.
Schreiter NF, Nogami M, Steffen I, Pape UF, Hamm B, Brenner W, Rottgen R: Evaluation of the potential of PET-MRI fusion for detection of liver metastases in patients with neuroendocrine tumours. Eur Radiol 2012;22:458-467.
29.
Beiderwellen K, Gomez B, Buchbender C, Hartung V, Poeppel TD, Nensa F, Kuehl H, Bockisch A, Lauenstein TC: Depiction and characterization of liver lesions in whole body (18F)-FDG PET/MRI. Eur J Radiol 2013;82:e669-675.
© 2015 S. Karger GmbH, Freiburg
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.